of their patients' psychological distress in order to identify high-risk patients and provide them with an appropriate psycho-oncological support.
INTRODUCTION AND OBJECTIVES: Alvimopan use in enhanced recovery programs has reduced the hospital length of stay (LOS) in patients undergoing major abdominal surgeries. Retroperitoneal lymph node dissection (RPLND) for testicular cancer may be associated with delayed GI recovery prolonging hospital LOS. In this study, we evaluate whether alvimopan is associated with enhanced GI recovery and shorter hospital LOS in men undergoing RPLND for testicular cancer.
METHODS: From 2010 to 2016, 29 patients underwent RPLND by a single surgeon (23 post-chemotherapy). All patients underwent bilateral template dissection. Data for patients who received alvimopan was prospectively collected and compared to a historical cohort of patients who did not receive alvimopan. Primary outcomes measured were hospital LOS and recovery of GI function. Mann-Whitney Wilcoxon and Chi square tests were used to determine statistical significance between the two groups. Kaplan-Meier survival curves were plotted and the log-rank test was utilized to compare treatment effects.
RESULTS: Of 29 men who underwent RPLND, 8 received alvimopan and 21 did not. There were no differences in preoperative or operative variables between the groups (Table 1) . Median hospital LOS for men receiving alvimopan was 4 days compared to 6 days for those who did not (p¼0.074). The median time to return of flatus in men receiving alvimopan was 2 days compared to 4 days for those who did not (p¼0.0023). The median time to first bowel movement (BM) in men receiving alvimopan was 2.5 days compared to 4 days for those who did not (p¼0.0028). Survival curves revealed that treatment intervention decreased both median time to event (time to flatus: 2 days vs. 4 days, log-rank test p-value<0.001; time to BM: 3 days vs. 5 days, log-rank test p-value<0.05; Figure 1 ) CONCLUSIONS: Alvimopan significantly reduced the median time to return of flatus and to first BM after RPLND. Furthermore, there was a trend towards shorter hospital LOS in those receiving alvimopan. 
Source of

INTRODUCTION AND OBJECTIVES:
Due to the rarity of penile cancer, there are no randomized studies evaluating the different treatment modalities for high stage disease. We used the National Cancer Database (NCDB) to determine factors associated with receiving adjuvant radiation and the influence on prognosis in men with Stage III (T1-3, N1-2) penile cancer who underwent inguinal lymph node dissection (ILND).
METHODS: The National Cancer Database (NCDB) was queried from 1998-2012 to identify men with penile cancer who had pathologic nodal status available. Clinical and pathologic variables associated with adjuvant radiation therapy were examined using chi square testing. Univariate and multivariate logistic regression was used to evaluate odds of receiving adjuvant radiation therapy, while Cox regression analysis evaluated whether adjuvant radiation influenced overall survival.
RESULTS: A total of 589 patients with stage III disease (T1-3, N1-2) underwent ILND. Adjuvant radiation was given in 23% of patients (N¼136). Mean age was 61.8 +/-13.7 years (median age 63, IQR 52-72). Patient age, year of diagnosis, Charlson comorbidity index, insurance status, income, education, stage, grade, tumor size, histology, LVI, extranodal extension (ENE), and primary surgery (partial vs. total penectomy) were not associated with receiving adjuvant radiation therapy. Factors associated with adjuvant radiation were higher pathologic nodal stage (OR 1.9, 95%CI 1.1-3.1), greater distance of travel (OR 0.5, 95%CI 0.3-0.9), and treatment in an academic setting (OR 0.5, 95%CI 0.3-0.8). Those receiving adjuvant radiation had a significant improvement in overall survival (HR 0.65, in the multivariate Cox regression analysis adjusting for year of diagnosis, age, race, Charlson comorbidity index, stage, grade, nodal status, and primary surgery. This benefit was notably attenuated when limited to N1 disease only (HR 0.86, 95%CI 0.36-2.06) versus to N2 disease only (HR 0.71, 95%CI 0.43-1.18).
CONCLUSIONS: Use of adjuvant radiation for stage III penile cancer is relatively common in the United States. The primary determinants of adjuvant radiation therapy are related to the proximity to cancer centers and greater nodal burden. We find evidence of a benefit with the use of adjuvant radiation, particularly in those with higher nodal disease burden (N2 vs. N1). As penile cancer remains a rare disease, multi-institutional studies are needed to improve treatment algorithms for high-stage disease. 197, No. 4S, Supplement, Monday, May 15, 2017 
